
Amicus Therapeutics, Inc. (FOLD)
Whether directors and officers of Amicus Therapeutics, Inc. (FOLD) breached their fiduciary duties to the company and its shareholders.
Investigation
02/28/2022
Initial Lawsuit
04/01/2022
Lawsuit Progression
05/31/2022
This investigation focuses on Lucid’s statements assuring rapidly increasing production capacity to reach yearly production targets.
02/28/2022
Lucid announces its Q4 2021 and fiscal year 2021 financial results. The company reveals that it delivered approximately 125 EVs in 2021, and produced approximately 400 EVs by February 28, 2022, will produce between 12,000 and 14,000 EVs in 2022, and will delay the launch of the Lucid Gravity until 2024.
“Looking ahead, we’re updating our outlook for 2022 production to a range of 12,000 to 14,000 vehicles. This reflects the extraordinary supply chain and logistics challenges we’ve encountered and our unrelenting focus on delivering the highest-quality products. We remain confident in our ability to capture the tremendous opportunities ahead given our technology leadership and strong demand for our cars,” Rawlinson added.
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$24.99 | $28.98 | $-3.99 | -13.77% |
This is a federal securities class action on behalf of a class of all persons and entities who purchased or otherwise acquired Lucid common stock between November 15, 2021, and February 28, 2022, inclusive.
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors that:
Defendants overstated Lucid’s production capabilities while concealing that “extraordinary supply chain and logistics challenges” were already significantly hampering the company’s operations.
The lead plaintiff deadline has passed, we will update this page as the lawsuit progresses.
Last event retrieved on 10/04/2022.
Whether directors and officers of Amicus Therapeutics, Inc. (FOLD) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Builders FirstSource, Inc. (BLDR) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Payoneer Global Inc. (PAYO) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Kewaunee Scientific Corporation (KEQU) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Inari Medical, Inc. (NARI) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of LegalZoom.com, Inc. (LZ) breached their fiduciary duties to the company and its shareholders.